ILLUCCIX
Total Payments
$1.6M
Transactions
5,378
Doctors
2,834
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $710,843 | 2,661 | 1,612 |
| 2023 | $521,601 | 2,166 | 1,380 |
| 2022 | $351,157 | 551 | 385 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $593,130 | 180 | 37.5% |
| Unspecified | $280,150 | 44 | 17.7% |
| Travel and Lodging | $244,759 | 382 | 15.5% |
| Honoraria | $190,433 | 106 | 12.0% |
| Food and Beverage | $179,235 | 4,633 | 11.3% |
| Education | $52,598 | 25 | 3.3% |
| Grant | $43,296 | 8 | 2.7% |
Payments by Type
General
$1.3M
5,334 transactions
Research
$280,150
44 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 68Ga PSMA-11 PET in Patients with Prostate Cancer | Telix Pharmaceuticals | $199,000 | 0 |
| potential clinical trial investigating PSMA in Radiation Therapy | Telix Pharmaceuticals | $21,200 | 0 |
| 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT forDetection of Invasive Lobular Breast Cancer:Interim Report from an Exploratory Trial | Telix Pharmaceuticals | $19,700 | 0 |
| Use of Illucix (68Ga PSMA-11) and uExplorer Total Body PET/CT Imaging | Telix Pharmaceuticals | $14,100 | 0 |
| Product doses for IIT study: 68-Ga-PSMA-11 PET in Patients with Prostate Cancer | Telix Pharmaceuticals | $12,200 | 0 |
| Pre-operative localization of parathyroid adenomas using GA-68 PSMA PET/CT | Telix Pharmaceuticals | $6,200 | 0 |
| Product doses for IIT study: Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes\00A0 | Telix Pharmaceuticals | $4,650 | 0 |
| Product doses for Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging | Telix Pharmaceuticals | $3,100 | 0 |
Top Doctors Receiving Payments for ILLUCCIX — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Diagnostic Radiology | Philadelphia, PA | $7,055 | 5 |
| , M.D | Urology | New Haven, CT | $6,675 | 11 |
| , M.D | Urology | La Mesa, CA | $5,995 | 12 |
| , MD | Diagnostic Radiology | Austin, TX | $5,945 | 6 |
| , M.D. PH.D | Nuclear Radiology | Hamden, CT | $5,910 | 15 |
| , MD | Medical Oncology | Stanford, CA | $5,564 | 10 |
| , MD | Nuclear Radiology | Iowa City, IA | $5,191 | 17 |
| , M.D | Diagnostic Radiology | Portland, OR | $5,000 | 2 |
| , MD | Nuclear Medicine | New York, NY | $4,489 | 6 |
| , M.D | Urology | Atlanta, GA | $4,473 | 3 |
| , M.D | Urology | Los Angeles, CA | $4,445 | 7 |
| , M.D | Internal Medicine | Honolulu, HI | $4,305 | 6 |
| , MD, MPH | Diagnostic Radiology | Boston, MA | $4,167 | 8 |
| , MD PHD | Nuclear Medicine | Boston, MA | $4,000 | 1 |
| , M.D | Diagnostic Radiology | New York, NY | $3,997 | 8 |
| , M.D | Radiation Oncology | Kennewick, WA | $3,948 | 1 |
| Michael Gorin | Urology | Greenlawn, NY | $3,875 | 5 |
| , MD | Nuclear Medicine | Houston, TX | $3,850 | 10 |
| , M.D | Urology | Glendale, CA | $3,500 | 1 |
| , M.D | Radiation Oncology | New York, NY | $3,393 | 3 |
| , MD | Diagnostic Radiology | Aurora, CO | $3,354 | 1 |
| , M.D | Medical Oncology | Boston, MA | $3,250 | 2 |
| , MD | Hematology & Oncology | Boston, MA | $3,200 | 5 |
| , ARNP | Family | Altamonte Springs, FL | $3,152 | 8 |
| , MD | Nuclear Medicine | Newark, NJ | $3,142 | 4 |
Ad
Manufacturing Companies
- Telix Pharmaceuticals $1.6M
Product Information
- Type Drug
- Total Payments $1.6M
- Total Doctors 2,834
- Transactions 5,378
About ILLUCCIX
ILLUCCIX is a drug associated with $1.6M in payments to 2,834 healthcare providers, recorded across 5,378 transactions in the CMS Open Payments database. The primary manufacturer is Telix Pharmaceuticals.
Payment data is available from 2022 to 2024. In 2024, $710,843 was paid across 2,661 transactions to 1,612 doctors.
The most common payment nature for ILLUCCIX is "Consulting Fee" ($593,130, 37.5% of total).
ILLUCCIX is associated with 8 research studies, including "68Ga PSMA-11 PET in Patients with Prostate Cancer" ($199,000).